StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Monday morning. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock opened at $0.40 on Monday. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $14.08. The firm has a market cap of $75.34 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average of $0.21 and a 200-day moving average of $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Sell-side analysts expect that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.